Navigation Links
Althea Technologies Acquires Altus Pharmaceuticals'(R) Assets and IP Portfolio, Establishing Technology Platform for Protein Formulations.
Date:5/2/2010

SAN DIEGO, May 2 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of services for biopharmaceutical development and manufacturing announced today that it has acquired the assets and IP portfolio of Altus Pharmaceuticals. The IP portfolio includes, among other things, Altus' Cross Linked Enzyme Crystal (CLEC®) and controlled release injectable technologies.  Applications of this protein crystal technology range from therapeutics to protein purification and catalysis. The controlled release injectable technology involves protein crystallization and complexation using customized manufacturing equipment installed at Althea.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020925/LAW010LOGO)

Additionally, the assets encompass a portfolio of product candidates based on these technologies which includes a seven day controlled release growth hormone injectable which has completed a phase 2 clinical trial. Althea was the manufacturer of the clinical supplies for this product candidate. Althea plans to enter into licensing discussions for these product candidates.

"We are delighted to acquire this portfolio of technologies which complements our core expertise in protein formulation and will bring added value to our customers' projects," commented Dr. Shabbir Anik, CEO of Althea Technologies. "We expect multiple applications for a broad range of proteins, peptides and vaccines addressing the need for controlled release, high concentration formulations, and stability," he added.

Althea will be exhibiting at the BIO International Convention: Booth #5940.

About Althea Technologies, Inc.

Althea Technologies is a fully integrated, contract development and manufacturing organization that provides services for plasmids, protein biologics and sterile products. Located in San Diego, CA, Althea offers cell banking, process development, cGMP protein & plasmid production, analytical development, formulation development, aseptic filling in vials & prefilled syringes, and lyophilization services for clinical development and commercialization.  For more information, visit www.altheatech.com.


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services
2. China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and the Fiscal Year Ended March 31, 2010 on June 4, 2010
3. China Medical Technologies to Participate in Investor Conferences in May and June 2010
4. CareFusion, Cerner to Integrate Technologies for Improved Hospital Safety, Efficiency
5. Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award
6. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
7. MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation
8. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
9. Abbott Completes Acquisition of STARLIMS Technologies
10. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
11. Rauland-Borg and Visonic Technologies Collaboration Brings Enhanced RTLS Functionality to the Responder 5(R) Nurse Call System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Fla. , Feb. 10, 2016 CSI ... today with the launch of the Specialty Pharmacy Podcast. ... an industry-first, aimed at providing real-world education, discussion and ... --> --> The ... and CEO of CSI Specialty Group Suzette DiMascio, CHE, ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
(Date:2/10/2016)... Feb. 10, 2016  The ALS Association, in partnership with ... Challenge to generate a biomarker to track TDP43 aggregation. The ... to a $1 million investment. --> ... that affects nerve cells in the brain and the spinal ... and control muscle movement, which often leads to total paralysis ...
Breaking Medicine Technology:
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit ... as the latest addition to its growing list of Partner Firms. S.S. ... Southeast, from Orlando to Huntsville and in between. , Harnessing the experience and ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... change in their patients. Research shows that the Goal Attainment Scale (GAS) captures ... overcome this challenge and learn more about the Goal Attainment Scale, Education Resources ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength ... solution that ensures the integrity of biological samples while operating at ultra-high pressures ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost ... Part D a decade ago, according to The Senior Citizens League (TSCL). ... they are coping with rapidly rising costs. “The implications are chilling, particularly for ...
Breaking Medicine News(10 mins):